Xiaojun Liu

2 months ago | cellandgene.com | Elben Guimaraes |Xiaojun Liu |Junwei Sun |Lucia Fernandez |Lucia Fernández

Each approach has its advantages and drawbacks. This guide should help you decide which one, or perhaps a hybrid strategy, is best for your company. Exploring Strategies For Developing Robust AAV PlatformsExplore advanced AAV production platforms that enhance efficiency, scalability, and compliance, paving the way for safe and accessible gene therapies.

Dec 13, 2024 | mdpi.com | Xiaojun Liu

2. Materials and Methods 2.1. Plant MaterialsA bush-type inbred line, CS82, and a wild-type inbred line, CM82, of pumpkin (C. maxima) were obtained from the high generations of self-crossing in our laboratory. The bush trait of CS82 (C. maxima) was transferred from the spontaneous bush-type mutant of pumpkin (C. moschata) found in Shanxi, China [27]. To analyze the inheritance of the bush trait in pumpkin (C. maxima), bush-type line CS82 and wild-type line CM82 were crossed to construct F1 generation.

Nov 22, 2024 | bioprocessintl.com | Xiaojun Liu |Brian Gazaille |Allan Bream |Tereza Pavlištová

Gene therapies are emerging as promising treatments for previously untreatable genetic disorders, with adeno-associated viruses (AAVs) being the preferred vector for gene delivery. However, AAV-based gene therapies face challenges in production, including cost, complexity, and scalability. With the gene therapy market projected to grow significantly, drug developers are seeking platforms that streamline AAV production.

Nov 22, 2024 | cellandgene.com | Xiaojun Liu

By Xiaojun Liu Gene therapies are rapidly transforming the treatment landscape for previously untreatable genetic disorders, offering new hope to patients worldwide. Among the various delivery methods, adeno-associated viruses (AAVs) have emerged as the vector of choice due to their safety profile and ability to target specific cells effectively.

Nov 21, 2024 | outsourcedpharma.com | Xiaojun Liu |Louis Garguilo

By Xiaojun Liu Gene therapies are rapidly transforming the treatment landscape for previously untreatable genetic disorders, offering new hope to patients worldwide. Among the various delivery methods, adeno-associated viruses (AAVs) have emerged as the vector of choice due to their safety profile and ability to target specific cells effectively.